Sign up
Pharma Capital

Paradigm Biopharmaceuticals director shows confidence with on-market share purchase

The company has begun discussions with International key opinion leaders for mucopolysaccharidoses (MPS) clinical trial design and site selection.
asx boards
Paradigm is focused on repurposing the drug pentosan polysulfate sodium.

Paradigm Biopharmaceuticals Ltd (ASX:PAR) director Christopher Fullerton has purchased 100,000 shares on-market for a total consideration of $118,116.

The transaction brings Fullerton’s total holding (direct and indirect) to 836,000 shares.

READ: Paradigm Biopharmaceuticals moving towards phase 2/3 MPS clinical trial

The company has begun discussions with International key opinion leaders (KOL’s) for mucopolysaccharidoses (MPS) clinical trial design and site selection.

MPS is a progressive rare disease caused by the absence or malfunctioning of lysosomal enzymes and has a severe unmet need.

Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form (iPPS), a US FDA approved drug that has a long track record of safely treating inflammation.

The company is confident that a single successful phase 2/3 clinical trial will enable iPPS to be registered as a treatment for certain MPS indications.

View full PAR profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.